Read more

December 11, 2023
4 min watch
Save

VIDEO: Faricimab may demonstrate better drying of pigment epithelial detachments

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Jennifer I. Lim, MD, discusses the effect of faricimab on pigment epithelial detachments.

Patients received monthly doses of either faricimab or aflibercept for the treatment of neovascular age-related macular degeneration. After 12 weeks, Lim and colleagues evaluated the drying effect of each drug.

Lim said there was not a difference between the two groups with fibrovascular pigment epithelial detachments (PEDs), but in serous PEDs, 3.9% of eyes treated with faricimab still had a serous PED component compared with 12.3% of eyes treated with aflibercept.

“It tells us that, indeed, the faricimab treatment could result in better drying of the PED compared to aflibercept, much like it does for all other fluid compartments,” Lim said.